General Hospital of Shenyang Military Region clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 0 with minor changes only.

1. Notable

   Head dOwn Position Before Endovascular Treatment for Large veSsel…Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)

   Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2027

   General Hospital of Shenyang Military Region·Not applicable· NCT07172789· Registry history of NCT07172789 on ClinicalTrials.gov (opens the registry)

   Updated Sep 18, 2026

2. Notable

   RICAMIS2 · Remote Ischemic Conditioning for Acute Moderate…RICAMIS2 · Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke

   Primary and study completion pushed from Dec 30, 2026 to Jun 30, 2027

   Also in this update: Enrollment increased: 960 → 1600 participants

   General Hospital of Shenyang Military Region·Not applicable· NCT06931535· Registry history of NCT06931535 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

3. Notable

   Change in Serum Biomarkers After Endovascular Treatment for Acute…Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion

   Primary and study completion pushed from Dec 30, 2026 to Dec 30, 2027

   Also in this update: Enrollment increased: 200 → 800 participants

   General Hospital of Shenyang Military Region·Not specified· NCT06383182· Registry history of NCT06383182 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

4. Notable

   Adding Evolocumab to Conventional Lipid-lowering Therapy for…Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

   Enrollment increased: 40 → 60 participants

   General Hospital of Shenyang Military Region·Not applicable· NCT07388420· Registry history of NCT07388420 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.